查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
非酒精性脂肪性肝炎治疗和诊断全球市场：按治疗剂、诊断剂、地区划分——规模、份额、展望、机会分析，2023-2030
市场调查报告书
商品编码
1233324

非酒精性脂肪性肝炎治疗和诊断全球市场：按治疗剂、诊断剂、地区划分——规模、份额、展望、机会分析，2023-2030

Non-alcoholic Steatohepatitis Therapeutics and Diagnostics Market, By Therapeutics, By Diagnostics, and By Geography - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030
出版日期: | 出版商: Coherent Market Insights | 英文 170 Pages | 商品交期: 2-3个工作天内

价格
简介目录

非酒精性脂肪性肝炎 (NASH) 是由肝臟中过多的脂肪细胞引起的肝臟炎症（脂肪肝病）。 当多余的脂肪变成肝臟炎症（肝臟肿胀）和纤维化（疤痕）时，就会发生这种情况。 由于 NASH 是一种隐性流行病，因此对安全有效的治疗和诊断的需求不断增长。

市场动态

患有 NASH 的人口不断增加，糖尿病和肥胖人口不断增加，对安全有效的 NASH 治疗和诊断的需求不断增加，政府和非政府组织的积极参与，对 NAFLD/NASH 的认识不断提高，这些都是预计将推动增长的关键因素预测期内全球非酒精性脂肪性肝炎 (NASH) 治疗和诊断市场。

例如，2022 年 6 月，Echosens 和 Novo Nordisk A/S 将推进非酒精性脂肪性肝炎 (NASH) 的早期诊断，并在患者、医疗保健提供者和其他利益相关者中进行推广。宣布合作以提高对非酒精性脂肪性肝炎 (NASH) 的认识疾病。 2018 年 6 月，世界肝臟研究所发起了第一个国际 NASH 日，以提高人们对 NASH 的认识以及人们可以采取的预防措施。

这项研究的主要特点

  • 本报告对全球非酒精性脂肪性肝炎 (NASH) 治疗和诊断市场进行了深入分析，其中包括以 2022 年为基准年的预测期（2023-2030 年）的市场规模和年復合数据。我们提供增长率（CAGR %）。
  • 它还阐明了各个细分市场的潜在创收机会，并描述了该市场具有吸引力的投资建议矩阵。
  • 它还提供有关市场驱动因素、制约因素、机会、新产品发布或批准、市场趋势、区域前景以及主要参与者采用的竞争策略的重要见解。
  • 根据以下参数对全球非酒精性脂肪性肝炎 (NASH) 治疗和诊断市场的主要参与者进行了介绍，这些参数包括公司亮点、产品组合、主要亮点、财务业绩和战略执行情况。
  • 本研究涵盖的主要公司包括
  • 这份报告中的见解将使营销人员和企业高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。
  • 《全球非酒精性脂肪性肝炎 (NASH) 治疗和诊断市场》报告面向该行业的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和金融分析师。与
  • 利益相关者可以通过用于分析全球非酒精性脂肪性肝炎 (NASH) 治疗和诊断市场的各种战略矩阵来促进决策制定。

这是目录。

第一章调查的目的和前提

  • 调查目的
  • 先决条件
  • 缩写

第二章市场范围

  • 报告内容
    • 市场定义和范围
  • 执行摘要
    • 按治疗剂分类的市场概况
    • 市场概况：按诊断剂分类
    • 市场概况：按地区
  • 连贯机会图 (COM)

第 3 章市场动态、法规和趋势分析

  • 市场动态
    • 全球 NASH 患者人数增加
    • 治疗领域进展缓慢
    • 对安全有效的治疗和诊断的需求不断增长
  • 影响分析
  • 主要亮点
  • 监管场景
  • 产品发布/批准
  • 害虫分析
  • 对 PORTER 的分析
  • 合併/收购场景

第 4 章非酒精性脂肪性肝炎 (NASH) 药物和诊断的全球市场 - 冠状病毒 (COVID-19) 大流行的影响

  • COVID-19 流行病学
  • 供应方和需求方分析
  • 经济影响

第 5 章非酒精性脂肪性肝炎 (NASH) 药物和诊断的全球市场：2017-2030

  • Elafibranol
  • 奥卡里巴
  • Theronsertive
  • Senikriviroku
  • 埃姆利卡桑
  • 其他治疗药物

第 6 章。全球非酒精性脂肪性肝炎 (NASH) 药物和诊断剂市场：2017-2030

  • 成像技术
  • 诊断测试
  • 活检

第 7 章按地区分列的非酒精性脂肪性肝炎 (NASH) 药物和诊断的全球市场，2017-2030

  • 北美
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东和非洲
  • 世界其他地区

第八章竞争格局

  • Novartis AG
  • Allergan Plc.
  • Viking Therapeutics
  • Merck & Co.
  • Zydus Cadila
  • Novo Nordisk A/S
  • GENFIT SA
  • Gilead Sciences Inc.
  • Galmed Pharmaceuticals
  • Madrigal Pharmaceuticals
  • Intercept Pharmaceuticals Inc.

第 9 章

  • 调查方法
  • 关于出版商
简介目录
Product Code: CMI2279

Non-alcoholic steatohepatitis (NASH) is inflammation of the liver caused by excess fat cells in it (fatty liver disease). It is caused when that extra fat turns into inflammation (swelling in the liver) and fibrosis (scarring) of the liver. NASH is a hidden epidemic, and thus, there is an increase demand for safe and effective therapeutics and diagnostics.

Market Dynamics:

Rise in NASH-affected population, increase in diabetic and obese population, increase in demand for safe and effective NASH therapeutics and diagnostics, favorable initiatives by government and non-government organizations, and increasing awareness about NAFLD/NASH are major factors expected to propel the growth of the global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market during the forecast period.

For instance, in June 2022, Echosens and Novo Nordisk A/S announced a collaboration to advance the early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers, and other stakeholders. In June 2018, the first International NASH Day was launched by Global Liver Institute with the goal of raising awareness about NASH and the actions people can take to prevent the disease.

Key features of the study:

  • This report provides in-depth analysis of the global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), considering 2022 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market.

Detailed Segmentation:

  • Global Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Therapeutics:
    • Elafibranor
    • Ocaliva
    • Selonsertib
    • Cenicriviroc
    • Emricasan
    • Other Therapeutics
  • Global Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Diagnostics:
    • Imaging Techniques
    • Diagnostic Tests
    • Biopsy
  • Global Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Geography:
    • North America
    • Europe
    • Asia-Pacific
    • Middle East and Africa
    • South America
  • Company Profiles:
    • Novartis AG
    • Allergan Plc.
    • Viking Therapeutics
    • Merck & Co.
    • Zydus Cadila
    • Novo Nordisk A/S
    • GENFIT SA
    • Gilead Sciences Inc.
    • Galmed Pharmaceuticals
    • Madrigal Pharmaceuticals
    • Intercept Pharmaceuticals Inc.

Table of Contents:

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Therapeutics
    • Market Snapshot, By Diagnostics
    • Market Snapshot, By Geography
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Rise in NASH-affected population worldwide
    • Slow advancements in the therapeutic field
    • Rise in demand for safe/effective therapeutics and diagnostics
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Therapeutics, 2017-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Elafibranor
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
  • Ocaliva
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
  • Selonsertib
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
  • Cenicriviroc
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
  • Emricasan
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
  • Other Therapeutics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)

6. Global Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Diagnostics, 2017-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Imaging Techniques
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
  • Diagnostic Tests
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
  • Biopsy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)

7. Global Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Geography, 2017-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
  • Middle East and Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
  • Rest of World
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)

8. Competitive Landscape

  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Allergan Plc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Viking Therapeutics
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Merck & Co.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Zydus Cadila
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Novo Nordisk A/S
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • GENFIT SA
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Gilead Sciences Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Galmed Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Madrigal Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Intercept Pharmaceuticals Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Analyst Views

9. Section

  • Research Methodology
  • About us